Merck Message Board - Msg: 3670009

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 106.54

+1.4%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EepOpp who wrote (618)	3/11/1998 8:02:00 AM
From: George Dawson	Read Replies (2) of 1580

Two favorable New England Journal of Medicine articles on Prilosec: Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338:719-26. Omeprazole was superior to zantac (ranitidine) for both healing and prevention - 79% vs. 63% and 72% vs. 59% respectively. Hawkey CJ, et al. Omeprazole campared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34. Acute treatment produced similar results for healing 76% (omeprazole) vs. 71% (misoprostol), but omeprazole was superior during maintenace therapy (61 vs 48%) and produced fewer adverse events (59 vs. 48%). George D.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next